Level C· Early human research exploring benefitsProspective StudyPubMed

Serum Leptin Exacerbates Osteoarthritis by Promoting Subchondral Bone H-Type Vessel Angiogenesis via Activation of the PI3K/AKT Pathway.

Li R., Xi Z., Luo S., Qin J., Liu T., Zhang J.

Prospective Study on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, published in J Cell Mol Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Cell Mol Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42374652
DOI
10.1111/jcmm.71232

Abstract (original English)

Osteoarthritis (OA) is a common degenerative joint disease closely associated with obesity. Adipokines secreted by adipose tissue play critical roles in disease progression. This study focuses on the adipokine leptin and investigates its relationship with knee osteoarthritis. Analysis of subchondral bone tissue from OA patients revealed decreased leptin receptor expression, enhanced osteogenic activity, and a significant increase in H-type vessel number. Concurrently, serum leptin levels were markedly elevated in OA patients. Animal experiments further demonstrated that leptin-knockout obese mice exhibited significantly milder OA, reduced H-type vessel formation, and decreased osteogenic activity. In contrast, mice with high serum leptin levels showed more severe joint destruction and vascular hyperplasia. In vitro cell experiments indicated that leptin activates the PI3K/AKT signalling pathway in bone marrow mesenchymal stem cells (BMSCs), increasing the secretion of angiogenic factors such as VEGF and HIF-1α. Conditioned medium from leptin-treated BMSCs promoted tube formation and expression of H-type vessel markers (EMCN/CD31) in mouse umbilical vein endothelial cells. Inhibition of the PI3K pathway using Ly294002 in BMSCs or ZSTK474 in mice abolished leptin's effects. These results suggest that obesity-induced hyperleptinemia drives aberrant H-type vessel angiogenesis and a

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
LeptinAnimalsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktHumansSignal TransductionMesenchymal Stem CellsOsteoarthritisMiceMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research